Comparative and Veterinary Pharmacology

Table 8

Pharmacokinetics of antimicrobial agents used for the treatment of bovine respiratory disease

Dose (mg/kg) Route

Cmax

(m

g/mL)

Tmax

(h) AUC (

mg h/mL) Terminal T

1/2

(h) F(%) References

Ceftiofur*

2.2

SC

13.6

0.67–3

108

9.5

NR

Brown et al. (2000)

Tilmicosin

10

SC

0.87

0.5

17.2

29.4

NR

Modric et al. (1998)

Tulathromycin

2.5

SC

0.41

0.25

11.9

92

>

90 Nowakowski et al. (2004)

Florfenicol

20

IM

3.1

3.3

70.7

18.3

78.5 Lobell et al. (1994)

Enrofloxacin** 8

SC

0.81

2.0

7.5

7.3

NR

TerHune et al. (2005)

12.5

SC

0.96

4.8

15

6.8

NR

Davis et al. (2007)

Oxytetracycline 10

IM

3.0

4.0

61.8

9.8

99.9 Schifferli et al. (1982)

*As ceftiofur sodium**

Parameters reported for the parent compound, enrofloxacin. Enrofloxacin represents approximately 59% of the total (enrofloxacin+ciprofloxacin) dru

g

concentrations in plasma (Davis et al. 2007) (ciprofloxacin is an active metabolite of enrofloxacin)NR: not reported

130 H. Benchaoui